Maternal Use of Antibiotics and the Risk of Congenital Malformations
NCT ID: NCT06770465
Last Updated: 2025-01-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
850000 participants
OBSERVATIONAL
2024-06-01
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Data were collected from publicly available reports in the U.S. Food and Drug Administration's Adverse Event Reporting System (FAERS), the Canada Vigilance Adverse Reaction (CVAR) database, and a population-based retrospective cohort in Xiamen, China. By applying multiple signal detection methods, we identified potential risk signals linking different antibiotic classes to organ-system-specific congenital malformations. For antibiotics showing positive signals, we further utilized a pregnancy medication cohort in Xiamen and applied causal inference techniques to estimate the adjusted relative risk of congenital malformations associated with first-trimester exposure to these antibiotics. Several sensitivity analyses-including both negative- and positive-control analyses-will also be performed.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Infection and Adverse Pregnancy Outcome
NCT02673216
Correlation Between Premature Rupture of Membranes and Early-onset Neonatal Infections
NCT03251898
Is the Vaginal Microbiome and Metabolome Associated With Spontaneous Preterm Birth (sPTB) in Multiple Pregnancies?
NCT06053697
Motherhood and Microbiome
NCT02030106
Biomarkers in Obstetrical Complications
NCT03480139
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Use of antibiotics during pregnancy in FAERS and CVAR databases
When using the publicly available spontaneous adverse event reporting databases FAERS and CVAR, the exposure group consists of reports of adverse events in pregnant individuals who used different types of antibiotics, and the control group consists of other adverse event reports in which no antibiotics were used.
Different categories of antibiotics
Use of different categories of antibiotics during pregnancy, such as quinolones and macrolides.
Use of antibiotics during pregnancy in a cohort in Xiamen, China
When using the pregnant women cohort data from Xiamen, China, the exposure group consists of pregnant individuals who used the target antibiotics of interest, while the control group is either those who did not use any antibiotics (blank control) or those who used penicillin (positive control).
Different categories of antibiotics
Use of different categories of antibiotics during pregnancy, such as quinolones and macrolides.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Different categories of antibiotics
Use of different categories of antibiotics during pregnancy, such as quinolones and macrolides.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
For the cohort study, all Xiamen pregnant women registered in the cohort were included
Exclusion Criteria
For cohort studies, pregnant women who were lost to follow-up were excluded, and pregnant women who were exposed to factors known to be associated with congenital malformations were excluded.
14 Years
65 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
West China Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sun Xin
professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xin Sun, PhD
Role: STUDY_CHAIR
Chinese Evidence-based Medicine Center, West China Hospital of Sichuan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The West China Hospital of Sichuan university
Chengdu, Sichuan, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Antibiotics and BDs
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.